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ABSTRACT
Background. Chronic kidney disease (CKD) entails a worse
cardiovascular outcome. The aim of our work was to study the
relationship between CKD and the achievement of recom-
mended targets for glycated haemoglobin (HbA1c), low-density
lipoprotein cholesterol (LDL-c) and blood pressure (BP) in a
real-life sample of patients with type 2 diabetesmellitus (T2DM).
Methods. We analysed a sample of 116 777 outpatients from
the Network of the Italian Association of Clinical Diabetolo-
gists; all patients had T2DM and at least one measurement
of HbA1c, LDL-c, BP, serum creatinine and albuminuria in
the year 2010. The outcome was the achievement of HbA1c,
LDL-c and BP values as recommended by International
Guidelines.
Results. In the entire sample, the mean value of HbA1c was 7.2 ±
1.2%, of LDL-c was 102 ± 33 mg/dL and of BP was 138/78 ± 19/
9 mmHg. CKD and its components were associated with poor
glycaemic and BP control, notwithstanding greater use of glu-
cose and BP-lowering drugs, while no association was found
with LDL-c values. Factors independently related to unsatisfac-
tory glycaemic control included female gender, body mass
index, duration of disease and high albuminuria. Men, older
people and those taking statins were more likely to reach
LDL-c target levels. Male gender, age and high albuminuria
strongly affected the achievement of BP targets.
Conclusions. CKD or its components, mainly high albumin-
uria, are associated with failure to reach therapeutic targets,
especially for HbA1c and BP, despite a greater use of drugs in
patients with T2DM.
Keywords: antihypertensive treatment, arterial hyper-
tension, cardiovascular risk factors, diabetic nephropathy,
hypercholesterolaemia
INTRODUCTION
The worldwide prevalence of diabetes is expected to reach 552
million subjects by 2030 [1]. Up to 40% of patients with type 2
diabetes mellitus (T2DM) develop some degree of renal impair-
ment over the course of their lifetime [2–4]. The presence of
albuminuria and/or the reduction in glomerular filtration rate
exert a severely unfavourable impact on patient outcome and
contribute significantly to increasing the cost of health care
for many national health systems worldwide [5]. Besides
being the most prevalent cause of end-stage renal disease in
Western countries, chronic kidney disease (CKD) is a well-
known risk multiplier and entails a dramatic increase in macro-
vascular complications [6, 7].
In the past several years it has consistently been shown that
glycaemic control as well as a reduction of cholesterol and blood
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macrovascular complications. As the current therapeutic ap-
proach to cardiovascular risk correction is graded and propor-
tional to each patient’s individual burden of risk, guidelines for
diabetes care recommend reaching specific treatment targets in
the presence of renal impairment [18–22].
Large-scale clinical studies however indicate that due to
a number of different possible reasons [23, 24], control of
risk factors is unsatisfactory in up to 50% of diabetic patients
[25–28] and therefore residual risk remains unacceptably ele-
vated. Investigating the residual gaps in quality of care and
their relationship with factors which may influence these gaps
may prove useful for devising more effective strategies to pre-
vent diabetic complications.
We therefore attempted to investigate the association of
CKD and its components with the achievement of recom-
mended therapeutic targets in a large cohort of patients with
T2DM attending outpatient diabetes clinics in Italy.
MATERIALS AND METHODS
The Italian health care system
All Italian citizens, regardless of social class or income, are
cared for by a general practitioner as part of the National Health
System. It is estimated that over three million citizens have been
diagnosed with diabetes in Italy. Care for peoplewith diabetes is
mainly provided by a public network of about 700 diabetes
clinics that provide diagnostic confirmation, therapy, preven-
tion and early diagnosis of complications through close patient
follow-up by a team of specialists and schedule regular check-
ups. Most patients are referred to these centres by their general
practitioner and care is free of charge [29–32].
Patients
In the present report we describe the results of an analysis of
a large sample of patients diagnosed with T2DM who were
followed-up at 294 diabetes centres in Italy. The analysis was
performed using the data set of electronic medical records
that were collected between 1 January 2010 and 31 December
2010. The centres involved in this study include about
one-third of all the Italian centres for diabetes, homogeneously
distributed throughout the country and therefore representative
of the Italian population suffering from T2DM.
Starting from a population of 510 247 patients with T2DM,
we identified a sample of 116 777 outpatients aged 18 years or
older with complete data for albuminuria, serum creatinine,
low-density lipoprotein cholesterol (LDL-c), HbA1c and BP.
In cases of multiple records collected during the year for the
same patient, the last available visit was included. Information
on the presence of diabetic retinopathy was also available.
Demographic and clinical characteristics of patients included
and excluded were similar, in particular with regard to the
prevalence of subjects reaching therapeutic targets for HbA1c,
LDL-c and BP (50 versus 51%, 50 versus 47% and 45 versus
45%, respectively).
Data collection
As already reported [28–31], the analysis of the database is
an attempt by the Italian Association of Clinical Diabetologists
(Associazione Medici Diabetologi, AMD; see Supplementary
Data) to identify a set of indicators that can be used in the con-
text of continuous quality improvement. Participating centres
adopted the same software systems for the everyday manage-
ment of outpatients, while a specially developed software pack-
age allowed us to extract the information we intended to analyse
from all the clinical databases (AMDData File). Moreover, data
from all participating centres were collected and centrally
analysed anonymously [29–32].
This initiative includes measuring and monitoring HbA1c,
BP, lipid profile (LDL-c or total and high-density lipoprotein
cholesterol and triglycerides). The use of specific classes of
drugs (insulin, statins and two or more antihypertensive
agents) was also evaluated. In the case of multiple entries during
the year, the most recent values were considered for the ana-
lyses. Because normal ranges for HbA1c varied among centres,
the percentage change with respect to the upper normal value
(measured value/upper normal limit) was estimated and multi-
plied by 6.0 in order to allow comparisons among the centres.
Kidney function was assessed by serum creatinine and urinary
albumin excretion measurements. Glomerular filtration rate
was estimated for each patient using a standardized serum cre-
atinine assay and the Chronic Kidney Disease Epidemiology
Collaboration formula [33]. Increased urinary albumin excre-
tion was diagnosed and defined as high albuminuria if the urin-
ary albumin concentration was >30 mg/L or urinary albumin
excretion rate was >20 µg/min or urinary albumin-to-creatinine
ratio was >2.5 mg/mmol in men and 3.5 mg/mmol in women.
CKDwas defined as diabetes with high albuminuria or low glom-
erular filtration rate (<60 mL/min/1.73 m2) or both.
For the purpose of the analysis, the target thresholds we con-
sidered in this study were <7% (53 mmol/mol) for HbA1c, and
<100 mg/dL for LDL-c according to the American Diabetes
Association’s (ADA) guidelines [19] and the Standard Italiani
per La Cura del Diabete Mellito 2014 [20]. Target BP threshold
was defined according to four clinical guidelines: the Clinical
Recommendations of the American Diabetes Association
and Standard Italiani per la Cura del Diabete Mellito 2014
(<140/80 mmHg) [19, 20], the European Society of Hyperten-
sion and the European Society of Cardiology (ESH-ESC)
(<140/85 mmHg) [21] and, finally, the KDIGO guidelines
(<140/90 or 130/80 mmHg in people with albuminuria) [22].
Statistical analysis
Continuous variables are expressed as mean ± standard de-
viation; discrete variables are described as frequencies and per-
centages. Between-group comparisons were not performed due
to the large sample size that allowed us to detect statistical sig-
nificance even for negligible differences. Data were analysed
using a mixed model with diabetes clinics fitted as random,
so that possible differences in data across centres could be con-
sidered. A multivariate mixed logistic regression model was fit-
ted to evaluate determinants of failure to reach recommended
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LDL-c ≥100 mg/dL or systolic BP ≥140 mmHg). Odds ratios
(OR) were reported with their 95% confidence interval (95%
CI). A missing indicator variable was used for patients with
missing smoker status. The analyses were made using STATA
software, Version 12 (StataCorp, College Station, Texas). P values
of <0.05 were considered statistically significant.
RESULTS
The main clinical features of the analysed population are sum-
marized in Table 1. Overall, the mean age was 67 ± 11 years,
56.7% were males and the mean duration of diabetes was
11 ± 9 years. Twenty-one per cent of patients had CKD stage
≥3, while high albuminuria was present in 26.9% of the popu-
lation. Taken as a whole, the population we studied had a mean
HbA1c level of 7.2 ± 1.2%, with 50.0% of the patients having
HbA1c levels below the target value. The mean level of LDL-c
was 102 ± 33 mg/dL and 50.6% of the patients had LDL-c below
the target value. Regarding BP control, the distribution of the
population was as follows: the ADA BP target (systolic/diastolic
BP <140/80 mmHg) was achieved by 25.7% of the patients
while the ESH-ESC BP target (systolic/diastolic BP <140/85
mmHg) was reached by 45.0% of the patients. Based on
KDIGO guidelines, we analysed patients with normoalbumi-
nuria or with high albuminuria separately: in the former
group the proportion of patients who reached BP target
(<140/90 mmHg) was 49.8%, while in the latter group BP target
(<130/80 mmHg) was reached by 13.3% of patients.
Considering the whole population, the proportion of pa-
tients who did not meet any of the recommended targets was
13.4%. Thirty-seven percent of patients met only one of the re-
commended therapeutic targets, 36.4% met two, and 13.4%
met all three.
The clinical characteristics of patients according to achieve-
ment of HbA1c, LDL-c and BP target values are reported in
Table 2. A higher percentage of patients with low estimated
glomerular filtration rate and high albuminuria was present
among those whose HbA1c was above the recommended
value: 22.7 versus 19.3% and 30.5 versus 23.2%, low estimated
glomerular filtration rate and high albuminuria, respectively.
Patients who did not meet HbA1c target values were more
often females and had a longer duration of disease; in addition,
they were on more intensive antihyperglycaemic treatment.
Regarding LDL-c, kidney dysfunction does not seem to impact
on the achievement of LDL-c target and, as expected, the pro-
portion of patients taking statins was greater among those with
LDL-c levels below the recommended values. As far as BP is
concerned, similarly to HbA1c, there clearly was a higher pro-
portion of patients with kidney dysfunction (especially those
with high albuminuria) among those who did not meet their
recommended targets. A greater number of patients taking
antihypertensive drugs, particularly angiotensin-converting
enzyme inhibitors or angiotensin II receptor blockers, was
also evident among these latter patients.
To get a more in-depth understanding of the relationship be-
tween kidney dysfunction and the achievement of HbA1c, LDL-c
and BP target values, we stratified the whole population according
to the presence/absence of low estimated glomerular filtration rate
or high albuminuria (Table 3). It would appear that high albumin-
uria, even more than low estimated glomerular filtration rate, af-
fects the chance of reaching HbA1c and BP target values, while it
bears no relationship with recorded LDL-c levels. It is noteworthy
that the lowest proportion of patients reaching HbA1c (42%) and
BP target levels (22.4%) was observed among patients with the
simultaneous presence of high albuminuria and low estimated
glomerular filtration rate even though the highest proportion of
patients taking more intensive antihyperglycaemic or anti-
hypertensive therapy (91.1%) was also found in the same group.
It is also evident that the presence of high albuminuria entails the
greatest difficulty in reaching BP target.
Table 1. Clinical features of 116 777 patients with T2DM
Male gender n (%) 66 260 (56.7)
Age (years) 67 ± 11
BMI (kg/m2) 30 ± 5
Serum creatinine (mg/dL) 0.97 ± 0.52
eGFR (mL/min/1.73 m2) 77 ± 21
eGFR < 60 mL/min/1.73 m2, n (%) 24 514 (21.0)
High albuminuria, n (%) 31 354 (26.9)
Known duration of diabetes (years) 11 ± 9
HbA1c (%) 7.2 ± 1.2
HbA1c < 7% (53 mmol/mol), n (%) 58 389 (50.0)
Total cholesterol (mg/dL) 178 ± 38
Triglycerides (mg/dL) 133 ± 76
HDL-c (mg/dL) 50 ± 14
LDL-c (mg/dL) 102 ± 33
LDL-c <100 mg/dL n (%) 59 037 (50.6)
SBP (mmHg) 138 ± 19
DBP (mmHg) 78 ± 9
SBP/DBP <140/80 mmHg 30 022 (25.7)
SBP/DBP <140/85 mmHg 52 562 (45.0)
Patients with normoalbuminuria (n = 85 423)
SBP/DBP <140/90 mmHg, n (%) 42 550 (49.8)
Patients with high albuminuria (n = 31 354)
SBP/DBP <130/80 mmHg n (%) 4177 (13.3)
Pulse pressure (mmHg) 60 ± 17
Retinopathy, n (%) 18 084 (15.5)
Smokers, n (%)a 11 887 (17.2)
Lipid-lowering treatment, n (%) 70 523 (60.4)
Treatment with statins, n (%) 65 114 (55.8)
Treatment with fibrates, n (%) 3 515 (3.0)
Antihypertensive treatment, n (%) 86 673 (74.2)
Treatment with ACE-Is/ARBs, n (%) 74 317 (63.6)
Aspirin, n (%) 39 436 (33.8)
Antidiabetic Rx
Diet n (%) 6099 (5.2)
OAD n (%) 74 112 (63.5)
OAD + insulin, n (%) 19 766 (16.9)
Insulin, n (%) 16 800 (14.4)
Patients with none of the variables below
the target value, n (%)
15 753 (13.4)
Patients with only one variable below
the target value, n (%)
42 943 (36.8)
Patients with two variables below
the target value, n (%)
42 465 (36.4)
Patients with all three variables below the target value, n (%) 15 616 (13.4)
eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL-c,
high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP,
systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin-converting
enzyme inhibitors; ARBs, angiotensin II receptor antagonists; OAD, oral antidiabetic
drugs.
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Table 3. Proportion of patients with T2DM stratified according to the achievement of therapeutic targets and their current treatment on the basis of the










HbA1c <7% (%) 53.4 48.4 43.6 42.0
LDL-c <100 mg/dL (%) 49.0 52.7 52.0 55.4
SBP/DBP <140/80 mmHg (%) 27.1 28.8 20.7 22.4
SBP/DBP <140/85 mmHg (%) 48.0 45.5 38.2 37.5
Patients with normoalbuminuria
SBP/DBP <140/90 mmHg (%) 50.4 47.0
Patients with high albuminuria
SBP/DBP <130/80 mmHg (%) 13.2 13.6
Lipid-lowering treatment (%) 58.0 64.1 63.0 66.6
Treatment with statins (%) 53.7 58.0 58.8 60.5
Treatment with fibrates (%) 2.7 4.3 2.7 3.9
Antihypertensive treatment (%) 67.7 87.5 78.9 91.1
Treatment with ACE-Is/ARBs (%) 57.5 74.4 70.3 77.5
Aspirin (%) 30.0 41.7 35.5 45.0
AntidiabeticRx
Diet (%) 6.2 4.9 3.3 2.6
OAD (%) 68.7 54.2 62.3 42.1
OAD + insulin (%) 14.8 17.3 22.0 20.5
Insulin (%) 10.2 23.5 12.4 34.9
Alb−, normoalbuminuria; Alb+, high albuminuria; eGFR−, estimated glomerular filtration rate ≥60 mL/min/1.73 m2; eGFR+, estimated glomerular filtration rate <60 mL/min/1.73 m2;
HbA1c, glycated haemoglobin; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure; ACE-Is, angiotensin-converting enzyme inhibitors;
ARBs, angiotensin II receptor antagonists; OAD, oral antidiabetic drugs.
Table 2. Clinical features of patients with T2DM divided according to the achievement of glycated haemoglobin, LDL-c and blood pressure target levels
HbA1c < 7% (53 mmol/mol) LDL-c < 100 mg/dL SBP/DBP < 140/85 mmHg
No
n = 58 388
Yes
n = 58 389
No
n = 57 740
Yes
n = 59 037
No
n = 64 215
Yes
n = 52 562
Male gender (%) 53.9 59.5 53.4 60.0 56.5 57.1
Age (years) 68 ± 11 67 ± 11 67 ± 11 68 ± 10 68 ± 10 66 ± 11
BMI (kg/m2) 30 ± 5 29 ± 5 30 ± 5 30 ± 5 30 ± 5 29 ± 5
Serum creatinine (mg/dL) 0.98 ± 0.52 0.97 ± 0.52 0.95 ± 0.51 0.99 ± 0.53 0.98 ± 0.53 0.96 ± 0.51
eGFR (mL/min/1.73 m2) 76 ± 21 78 ± 20 78 ± 21 76 ± 21 76 ± 20 78 ± 21
eGFR <60 mL/min/1.73 m2 (%) 22.7 19.3 19.6 22.3 22.0 19.7
High albuminuria (%) 30.5 23.2 25.5 28.2 30.3 22.7
Known duration of diabetes (years) 13 ± 9 9 ± 8 10 ± 9 12 ± 9 11 ± 9 11 ± 9
HbA1c (%) 8.1 ± 1.1 6.3 ± .5 7.2 ± 1.3 7.1 ± 1.2 7.2 ± 1.2 7.1 ± 1.2
Total cholesterol (mg/dL) 179 ± 39 177 ± 37 205 ± 30 152 ± 24 180 ± 38 176 ± 38
Triglycerides (mg/dL) 140 ± 85 125 ± 64 137 ± 69 129 ± 81 134 ± 73 131 ± 79
HDL-c (mg/dL) 50 ± 14 51 ± 14 51 ± 13 49 ± 15 51 ± 14 50 ± 14
LDL-c (mg/dL) 102 ± 33 102 ± 32 128 ± 24 77 ± 16 103 ± 33 101 ± 32
SBP (mmHg) 139 ± 19 137 ± 18 139 ± 19 137 ± 18 150 ± 15 123 ± 9
DBP (mmHg) 78 ± 10 78 ± 9 79 ± 10 77 ± 9 82 ± 9 73 ± 7
Pulse pressure (mmHg) 61 ± 17 59 ± 16 60 ± 17 60 ± 16 68 ± 16 49 ± 9
Retinopathy (%) 20.1 10.9 13.7 17.2 16.9 13.8
Smokers (%) 17.5 16.9 17.7 16.6 15.3 19.4
Lipid-lowering treatment (%) 61.9 58.9 50.3 70.2 60.6 60.1
Treatment with statins (%) 57.1 54.4 45.2 66.1 56.0 55.4
Treatment with fibrates (%) 3.1 2.9 3.4 2.6 3.1 2.9
Antihypertensive treatment (%) 75.0 73.4 69.2 79.1 78.8 68.6
Treatment with ACE-Is/ARBs (%) 64.6 62.7 58.9 68.3 69.0 57.1
Aspirin (%) 35.7 31.8 28.9 38.5 35.6 31.6
Antidiabetic Rx
Diet (%) 1.1 9.4 6.6 3.9 4.8 5.8
OAD (%) 54.3 72.6 64.5 62.5 63.3 63.7
OAD + insulin (%) 25.5 8.3 15.2 18.6 18.1 15.5
Insulin (%) 19.1 9.7 13.8 15.0 13.9 15.0
HbA1c, glycated haemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure;
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Finally, by means of multivariate analysis, we explored the
independent correlates of the achievement of recommended
therapeutic targets (Table 4). Younger subjects, females with
higher body mass index, longer duration of disease and high al-
buminuria were less likely to achieve HbA1c target values.
Males, the elderly and those taking statins were more likely to
reach LDL-c target levels. Male gender, age and high albumin-
uria, regardless of low estimated glomerular filtration rate,
strongly affected the achievement of BP targets.
We further analysed the association of CKD with various BP
target values (Table 5) according to the above reported guidelines
[19–22]. Overall, results confirm an association between male
gender, age, body mass index, HbA1c, LDL-c and the presence
of microvascular complications, including retinopathy and high
albuminuria with failure to achieve recommended BP control.
DISCUSSION
In a large sample of adults with diabetes attending a network of
National Health System outpatient clinics and representative of
real-life care in Italy, we found that only ∼13% of patients
achieved recommended treatment goals for all three parameters
we examined, while∼36–37% had either one or two out of three
indicators within target levels, and 13% were found to be outside
the recommended targets for all parameters. It is surprising that
87% of patients did not meet all three target levels simultan-
eously. The proportion of patients reaching recommended tar-
gets was disappointingly low in the presence of CKD, especially
high albuminuria. Conversely renal abnormalities were not as-
sociated with the failure in the achievement of LDL-c targets.
Therapeutic strategies aimed at correcting multiple risk fac-
tors, namely hyperglycaemia, increased cholesterol levels and
hypertension in patients with T2DM have proven to significant-
ly reduce the risk ofmicro- andmacrovascular complications as-
sociated with diabetes [8–17]. Accordingly, current guidelines
recommend specific, often tighter therapeutic goals based on
the risk burden of each individual patient [19–22]. However,
previous studies in the USA and elsewhere [25–30] have re-
ported that a relatively low number of patients with T2DM
reach recommended therapeutic levels for traditional, modifi-
able risk factors. Thus, our findings seem to confirm and extend
what has very recently been reported by the NHANES study, i.e.
that although there have been improvements over the last dec-
ade, almost half of American adults with diabetes do not meet
the recommended goals for diabetes care [28].
Recommended target levels of HbA1c were reached by only
half of the patients and by an even lower number (42%) in the
presence of low estimated glomerular filtration rate and/or high
albuminuria, indicating that the proportion of diabetic patients
meeting the recommended HbA1c target is still far from satis-
factory. Although the need for caution has recently been em-
phasized [19, 20], results from the main clinical trials and
surveys [8–11] confirm the benefits of glycaemic control in re-
ducing the risk of the onset and progression of micro- and
macrovascular complications. This has translated into more
stringent recommended HbA1c targets for the majority of pa-
tients [19, 20]. Shurraw et al. have recently shown that higher
Table 4. Determinants of failure to reach recommended therapeutic targets
HbA1c≥ 7% (53 mmol/mol) LDL-c≥ 100 mg/dL SBP≥ 140 mmHg
Odds ratio (95% CI) P Odds ratio (95% CI) P Odds ratio (95% CI) P
Male gender 0.802 (0.779–0.825) <0.001 0.727 (0.709–0.746) <0.001 1.024 (0.998–1.052) 0.075
Age (by 5 years) 0.984 (0.976–0.991) <0.001 0.972 (0.965–0.979) <0.001 1.162 (1.154–1.171) <0.001
BMI (by 1 kg/m2) 1.025 (1.023–1.028) <0.001 0.999 (0.996–1.001) 0.256 1.032 (1.030–1.035) <0.001
Known duration of
diabetes (by 1 year)
1.032 (1.030–1.034) <0.001 0.991 (0.989–0.992) <0.001 1.005 (1.003–1.007) <0.001
HbA1c (by 1%) 1.079 (1.066–1.091) <0.001 1.044 (1.031–1.056) <0.001
LDL-c (by 10 mg/dL) 1.024 (1.019–1.028) <0.001 1.032 (1.028–1.036) <0.001
SBP (by 10 mmHg) 1.036 (1.028–1.045) <0.001 1.066 (1.058–1.073) <0.001
Retinopathy 1.159 (1.113–1.207) <0.001 0.905 (0.872–0.939) <0.001 1.225 (1.180–1.272) <0.001
Smokers 1.087 (1.038–1.138) <0.001 1.056 (1.011–1.102) 0.014 0.847 (0.811–0.884) <0.001
Lipid-lowering treatment 1.127 (1.094–1.161) <0.001 0.502 (0.489–0.516) <0.001 0.962 (0.935–0.989) 0.006
Antihypertensive treatment 0.827 (0.785–0.871) <0.001 0.752 (0.717–0.789) <0.001 1.094 (1.043–1.149) <0.001
Treatment with ACE-Is/ARBs 1.010 (0.965–1.057) 0.664 0.985 (0.945–1.027) 0.469 1.436 (1.377–1.497) <0.001
Aspirin 1.033 (1.002–1.066) 0.038 0.833 (0.810–0.857) <0.001 1.016 (0.987–1.046) 0.271
Antidiabetic Rx
Diet 0.144 (0.132–0.157) <0.001 1.538 (1.450–1.631) <0.001 0.926 (0.873–0.982) 0.010
OAD Reference Reference Reference
OAD + insulin 3.975 (3.811–4.146) <0.001 0.811 (0.781–0.842) <0.001 1.003 (0.965–1.042) 0.877
Insulin 2.415 (2.314–2.520) <0.001 0.901 (0.865–0.938) <0.001 0.845 (0.811–0.880) <0.001
High albuminuria and low eGFR
Alb−/eGFR− Reference Reference Reference
Alb−/eGFR+ 0.963 (0.921–1.008) 0.104 1.004 (0.963–1.046) 0.851 0.789 (0.756–0.822) <0.001
Alb+/eGFR− 1.336 (1.285–1.388) <0.001 1.001 (0.966–1.038) 0.942 1.415 (1.364–1.467) <0.001
Alb+/eGFR+ 1.072 (1.016–1.132) 0.011 0.991 (0.943–1.041) 0.713 1.130 (1.075–1.188) <0.001
HbA1c, glycated haemoglobin; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure; ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor
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HbA1c levels were strongly and independently associated with
excess risk of renal and cardiovascular outcomes in a large
population with T2DM and CKD. Furthermore, they found
that the relationship between glycometabolic control and mor-
tality was U-shaped, with a significantly greater risk for HbA1c
values both below 6.5% (48 mmol/mol) and above 8.0% (64
mmol/mol) [18].
A number of other factors, such as gender, age, duration of
disease and household income, have been evoked to explain the
observed failure to reach HbA1c target levels. To the best of our
knowledge this is the first study investigating the potential role
of kidney dysfunction in this regard. Noteworthy, CKD and its
components, mainly high albuminuria, were more frequent
among patients with HbA1c ≥7% (53 mmol/mol), despite
a greater use of glucose-lowering agents. Moreover, when a
multivariate analysis model was performed, kidney dysfunction
turned out to be strongly and independently associated with a
lower probability of meeting recommended HbA1c targets.
As there is some heterogeneity among various guidelines re-
garding the recommended target values for BP, we explored dif-
ferent thresholds for optimal BP control. Only about one out of
two patients resulted on target when either ADA (<140/80
mmHg) [19] or ESH-ESC (<140/85 mmHg) [21] recom-
mendations were considered, a percentage that dropped dra-
matically when a more stringent value (<130/80 mmHg) was
considered in the subgroup of patients with high albuminuria.
These results are even more noteworthy when one considers
that patients with CKD or one of its components received, on
average, more antihypertensive drugs including agents that
block the rennin–angiotensin–aldosterone system as compared
with those with normal renal function, thus reducing the
likelihood that therapeutic inertia may play a role. Accordingly,
in the multivariate analysis kidney dysfunction, high albumin-
uria mainly emerges as a significant and independent predictor
of failure to achieve therapeutic target levels.
As for cholesterol levels, data from the AMD network data-
base indicate that the use of statins is associated with lower
LDL-c levels. However, even when assuming a target LDL-c
level <100 mg/dL regardless of each patient’s specific clinical
status or risk profile [19, 20], the number of patients reaching
recommended values does not exceed 50%. These data suggest
that although the use of statins in diabetic patients has risen
over the last decade [34], considerable gaps remain to be filled
before reaching a satisfactory standard of care in the real-life
clinical setting. Interestingly, at variance with what we observed
for BP and glycaemic control, our data seem to convey a some-
what different picture with respect to lipid levels in the presence
of CKD. In fact, LDL-c levels and prevalence of patients reach-
ing their recommended cholesterol target are almost superim-
posable in patients with and without CKD. The percentage
of diabetic patients receiving a statin was even greater in the
presence of renal complications (high albuminuria and/or esti-
mated glomerular filtration rate reduction), suggesting that the
presence of CKD is perceived as a condition of increased car-
diovascular risk by diabetologists. The significant association
we found between insulin or angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers treatment and not
achieving HbA1c or BP target values, respectively, is likely
due to an indication bias since the presence of CKD greatly lim-
its pharmacological options for antidiabetic treatment and is
widely taken as a mandatory indication for the use of renin–
angiotensin–aldosterone system inhibitors.
Table 5. Determinants of failure to reach different recommended blood pressure targets
SBP≥ 140/80 mmHg SBP≥ 140/85 mmHg
Odds ratio (95% CI) P Odds ratio (95% CI) P
Male gender 1.057 (1.026–1.089) <0.001 1.057 (1.029–1.085) <0.001
Age (by 5 years) 1.042 (1.034–1.050) <0.001 1.111 (1.103–1.119) <0.001
BMI (by 1 kg/m2) 1.047 (1.044–1.050) <0.001 1.038 (1.036–1.041) <0.001
Known duration of diabetes (by 1 year) 0.998 (0.996–0.999) 0.011 1.002 (1.001–1.004) 0.004
HbA1c (by 1%) 1.055 (1.040–1.069) <0.001 1.051 (1.038–1.063) <0.001
LDL-c (by 10 mg/dL) 1.036 (1.031–1.041) <0.001 1.035 (1.031–1.039) <0.001
Retinopathy 1.132 (1.084–1.181) <0.001 1.192 (1.148–1.238) <0.001
Smokers 0.806 (0.769–0.845) <0.001 0.846 (0.810–0.883) <0.001
Lipid-lowering treatment 0.943 (0.913–0.973) <0.001 0.946 (0.920–0.973) <0.001
Antihypertensive treatment 1.076 (1.021–1.135) 0.006 1.095 (1.043–1.148) <0.001
Treatment with ACE-Is/ARBs 1.363 (1.301–1.428) <0.001 1.418 (1.360–1.478) <0.001
Aspirin 0.970 (0.938–1.003) 0.070 0.997 (0.968–1.026) 0.824
Antidiabetic Rx
Diet 0.957 (0.897–1.021) 0.180 0.930 (0.877–0.985) 0.014
OAD Reference Reference
OAD + insulin 0.928 (0.888–0.970) 0.001 0.980 (0.943–1.019) 0.309
Insulin 0.752 (0.719–0.786) <0.001 0.816 (0.783–0.850) <0.001
High albuminuria and low eGFR
Alb−/eGFR− Reference Reference
Alb−/eGFR+ 0.777 (0.742–0.814) <0.001 0.802 (0.769–0.836) <0.001
Alb+/eGFR− 1.336 (1.279–1.394) <0.001 1.399 (1.349–1.451) <0.001
Alb+/eGFR+ 1.124 (1.060–1.191) <0.001 1.150 (1.093–1.210) <0.001
HbA1c, glycated haemoglobin; LDL-c, low-density lipoprotein cholesterol; SBP, systolic blood pressure; ACE-Is, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor
antagonists; OAD, oral antidiabetic drugs; Alb−, normoalbuminuria; Alb+, high albuminuria; eGFR, estimated glomerular filtration rate; eGFR−, eGFR ≥60 mL/min/1.73 m2; eGFR+,
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Taken together, the data presented here indicate a large area
of potential therapeutic improvement that could optimize car-
diovascular risk profile and therefore prevent further micro- and
macrovascular complications. Several implications of our re-
sults deserve to be commented upon. The persisting gaps in
care depicted in our study might, in principle, be due to the
interaction of different factors involving patients (lack ofmotiv-
ation), care providers (therapeutic inertia) or, lastly and more
generally, health systems (logistical or financial barriers for
patient access to care). In this study we specifically wanted to
investigate whether the presence of CKD may be a factor asso-
ciated with failure to achieve treatment goals, and we believe
that the results presented herein clearly indicate that this is
the case, at least for glycaemic control and BP. While the cross-
sectional nature of this study does not allow us to draw any de-
finitive pathophysiological conclusions, we feel our data suggest
that impairment of renal functionmay hamper the effectiveness
of antihypertensive treatment and impose limits on the choice
of hypoglycaemic drugs in clinical practice while altering the
risk–benefit ratio. Although a detailed analysis of the reasons
for this disappointing situation is clearly beyond the scope of
this study, our data showing a slightly but significantly greater
percentage of statin treatment in the subgroup of patients with
CKD suggest that therapeutic inertia towards a high-risk situ-
ation cannot be claimed as the major or sole cause in the thera-
peutic failure that we observed. This is further supported by the
observation that, likely thanks to a greater awareness of thewell-
known high-risk status and possibly stronger therapeutic effort
associated with this condition, the prevalence of patients receiv-
ing a statin was higher in the presence of CKD or even only of
one of its components. On the other hand, we cannot exclude
that the worse glycaemic and BP control we observed is itself
causative of kidney damage. Thus, an alternate hypothesis to
explain our results is that patients under suboptimal glycaemic
and BP control are in a higher proportion to those with renal
impairment. In this regard, the relatively low use of
angiotensin-converting enzyme inhibitors/angiotensin II re-
ceptor blockers in our sample is alarming, especially in pa-
tients with documented high albuminuria.
From the standpoint of public health and economics, our re-
sults seem to indicate the need to reiterate widespread diffusion
and implementation of therapeutic guidelines and recommen-
dations to further reduce the residual risk of diabetic patients,
especially those with CKD. This would certainly lead to a fur-
ther reduction in morbidity and mortality and consequently a
containment of costs for the National Health System. Further-
more, specific studies aimed at improving treatment strategies
for patients with CKD are clearly needed to help close the
gap in diabetes care.
Some limitations of our study should be acknowledged. First
of all, laboratory parameters were not measured in a single cen-
tralized laboratory and this may have led to considerable vari-
ability, especially in the evaluation of serum creatinine (and
therefore glomerular filtration rate estimation). Although cre-
atinine determination cannot always be referred to IDMS pro-
cedures, most laboratories around the country currently use the
Jaffè method, which has been shown to have good
reproducibility. In addition, we have information on high albu-
minuria only as a categorical trait.
On the other hand, our study has several strengths since the
large size of the database and the homogeneous geographical
distribution of participating centres allow us to provide a real-
istic snapshot of risk-factor control and preventive practices in a
real life situation representative of the Italian health care system.
In conclusion, our findings provide evidence that the pres-
ence of CKD and its individual components, especially high al-
buminuria, are associated with a greater likelihood of failure to
achieve recommended therapeutic targets for BP and glycaemic
control in diabetic patients. Further longitudinal specifically de-
signed studies will better clarify our observations and should
aim at breaking down barriers which decrease the chance to
achieve guideline recommendations.
SUPPLEMENTARY DATA
Supplementary data are available online at http://ndt.oxford
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